Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Tacrolimus
In hepatic transplant patients initiated on mycophenolate mofetil and tacrolimus, the AUC and Cmax of
MPA, the active metabolite of mycophenolate mofetil, were not significantly affected by co-
administration with tacrolimus. In contrast, there was an increase of approximately 20% in tacrolimus
AUC when multiple doses of mycophenolate mofetil (1.5 g BID) were administered to hepatic
transplant patients taking tacrolimus. However, in renal transplant patients, tacrolimus concentration
did not appear to be altered by mycophenolate mofetil (see also section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Tacrolimus
In hepatic transplant patients initiated on mycophenolate mofetil and tacrolimus, the AUC and Cmax of
MPA, the active metabolite of mycophenolate mofetil, were not significantly affected by co-
administration with tacrolimus. In contrast, there was an increase of approximately 20% in tacrolimus
AUC when multiple doses of mycophenolate mofetil (1.5 g BID) were administered to hepatic
transplant patients taking tacrolimus. However, in renal transplant patients, tacrolimus concentration
did not appear to be altered by mycophenolate mofetil (see also section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Tacrolimus
In hepatic transplant patients initiated on mycophenolate mofetil and tacrolimus, the AUC and Cmax of
MPA, the active metabolite of mycophenolate mofetil, were not significantly affected by co-
administration with tacrolimus. In contrast, there was an increase of approximately 20% in tacrolimus
AUC when multiple doses of mycophenolate mofetil (1.5 g BID) were administered to hepatic
transplant patients taking tacrolimus. However, in renal transplant patients, tacrolimus concentration
did not appear to be altered by mycophenolate mofetil (see also section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Tacrolimus
In hepatic transplant patients initiated on mycophenolate mofetil and tacrolimus, the AUC and Cmax of
MPA, the active metabolite of mycophenolate mofetil, were not significantly affected by co-
administration with tacrolimus. In contrast, there was an increase of approximately 20% in tacrolimus
AUC when multiple doses of mycophenolate mofetil (1.5 g BID) were administered to hepatic
transplant patients taking tacrolimus. However, in renal transplant patients, tacrolimus concentration
did not appear to be altered by mycophenolate mofetil (see also section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-05-07T14:22:00Z · SHA-256 8464b0a5294445d85b3f9b902633989ca6f57af3990241a80eda4979936ba419 · Passage 336922794df91683bbd279ca81ccc01c2dc0d0a5c1f000eebf9915e882b54ddb · Zeichen 7286–7863 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.